Blog
RSS FeedPosted by Michael Wonder on 02 Oct 2018
Denmark funds Vertex’s cystic fibrosis drug Orkambi, UK talks deadlocked
2 October 2018 - As uncertainty hangs over the availability of Vertex’s cystic fibrosis drug in England, the company has ...
Posted by Michael Wonder on 01 Oct 2018
NHS England agrees to fund Janssen’s Symtuza
1 October 2018 - NHS England has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen ...
Posted by Michael Wonder on 01 Oct 2018
Age-related macular degeneration: treatment at what cost?
29 September 2018 - An estimated 8·4 million people worldwide have moderate to severe vision loss caused by age-related macular degeneration. ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 27 Sep 2018
Differentiation of health-related quality of life outcomes between five disease areas: results from an international survey of patients
25 September 2018 - Health-related quality of life data generated by generic, preference-based instruments are highly demanded in health policy decision ...
Posted by Michael Wonder on 27 Sep 2018
Draft NICE decision rejects Respreeza for incurable, genetic disorder
27 September 2018 - NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in ...
Posted by Michael Wonder on 26 Sep 2018
Quality assurance of registries for health technology assessment
25 September 2018 - The aim of this study was to identify guidelines and assessment tools used by health technology agencies ...
Posted by Michael Wonder on 25 Sep 2018
Patients call for end to CF drug price row at key meeting
25 September 2018 - Representatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to ...
Posted by Michael Wonder on 23 Sep 2018
NHS wins legal battle against drugs giants over saving millions with cheaper medicine
21 September 2018 - The NHS has won a landmark battle against drug giants paving the way for the health ...
Posted by Michael Wonder on 20 Sep 2018
Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?
21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions. ...
Posted by Michael Wonder on 19 Sep 2018
Truvada ruling could allow cheap HIV prevention in the UK
19 September 2018 - Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk ...
Posted by Michael Wonder on 19 Sep 2018
NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma
19 September 2018 - The National Institute for Health and Care Excellence has turned down NHS funding for use of ...
Posted by Michael Wonder on 19 Sep 2018
NICE encourages further discussions on Kymriah for adult lymphoma
19 September 2018 - CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft ...
Posted by Michael Wonder on 17 Sep 2018
Targeted treatment for melanoma to be free on NHS
17 Septembre 2018 - Hundreds of patients with a type of aggressive skin cancer will be offered a targeted therapy ...
Posted by Michael Wonder on 17 Sep 2018
Patients with high-risk skin cancer have new treatment option
17 September 2018 - Hundreds of patients with a type of advanced skin cancer are set to benefit from a new ...